Comparative Pharmacology
Head-to-head clinical analysis: FOLOTYN versus RITUXAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLOTYN versus RITUXAN.
FOLOTYN vs RITUXAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOLOTYN (pralatrexate) is a folate analogue metabolic inhibitor that competes for the reduced folate carrier and folylpolyglutamate synthetase, leading to intracellular accumulation of polyglutamated metabolites that inhibit dihydrofolate reductase (DHFR) and thymidylate synthase, thereby disrupting DNA synthesis and cell proliferation.
Rituximab is a chimeric monoclonal antibody that binds specifically to the CD20 antigen on pre-B and mature B-lymphocytes. Binding induces complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), leading to B-cell depletion.
3.0 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
375 mg/m2 IV weekly for 4 doses for non-Hodgkin lymphoma; 1000 mg IV on days 1 and 15 for rheumatoid arthritis; 375 mg/m2 IV weekly for 4 doses for chronic lymphocytic leukemia (in combination with fludarabine and cyclophosphamide).
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours; clinical context: supports weekly dosing schedule.
Mean terminal elimination half-life is approximately 22 days (range 6.1–52 days) after first dose, decreasing to about 6 days after fourth dose due to target-mediated clearance. Clinical context: Extended half-life allows for weekly or every-2-week dosing; half-life shortens with repeated dosing due to B-cell depletion.
Primarily renal excretion (approximately 80% of the dose recovered in urine over 24 hours, with about 60% as unchanged drug); biliary/fecal elimination accounts for <1%.
Rituximab is eliminated primarily via reticuloendothelial system metabolism and target-mediated clearance. Renal excretion is negligible (<1% of dose as intact antibody in urine). Biliary/fecal excretion is minimal. Clearance is influenced by tumor burden and CD20 expression.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent